United States
Healthcare

June 4, 2022

Edward Woo, CFA
(949) 259-4932
ewoo@ascendiant.com

AIM ImmunoTech Inc.

Q1 about inline. Clinical data expected to be strong catalysts for stock over the next year. Lowering P/T to $7.50.

COMPANY UPDATE

Rating: BUY

Ticker: AIM

Price: $0.93

Target: $7.50
(from $8.00)

Q1 about inline: AIM recently (on May 16) reported its Q1 2022 (ending March) results. Net loss was $3.8 million or EPS of $(0.08), compared with our and consensus estimates of $(0.07) – (0.09). There was no guidance. AIM is an early/clinical stage drug development/commercialization company so it generates minimal revenue.

Q1 update: Operating expenses were $3.1 million, vs. $3.5 million in Q1 2021 as the company continues its clinical trial and research activities.

No guidance: Management did not provide forward guidance but we believe ~$4 million is a reasonable near term quarterly cash burn rate.

Adjusting estimates: We are adjusting our 2022 EPS estimate to $(0.33) from $(0.37).

Positive data from 2 studies: In April, AIM announced positive data from a Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM's drug candidate, Ampligen. AIM also announced positive data from a Phase 2a study (also at Roswell Park) evaluating Ampligen as a component of a chemokine modulatory (CKM) regimen for the treatment of colorectal cancer metastatic to the live.

Potential COVID-19 treatment: The extent (spread and effect) of the global pandemic of the new coronavirus (2019-nCoV) and COVID-19 has exploded globally (since early 2020) and even with vaccines widely used, it is still spreading due to new and changing variants (i.e. Delta and Omicron).

Numerous COVID-19 studies underway: The company is planning a major Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza. The goal is to establish Ampligen's potential as a broad spectrum prophylaxis for respiratory viruses, including SARS-CoV-2. There are also various other COVID-19 studies planned or underway currently (in the U.S. and international).

Ramp up in clinical trials: A major Phase 2 study for Ampligen for pancreatic cancer is expected to start in Q3 2022. In collaboration with major cancer research centers in the U.S., clinical trials are underway to test that the combination of Ampligen with checkpoint blockade therapies will improve clinical tumor responses, time to progression, and survival rates. There are seven cancer clinical trials underway or planned at the University of Pittsburgh Medical Center and Roswell Park Comprehensive Cancer Center.

Clinical data can be catalyst: AIM anticipates receiving additional clinical data from its various trials over the next year. Initial and recent data has been positive and further strong positive data will likely be catalysts for the stock.

Positive high risks versus rewards: We acknowledge that AIM's oncology drugs still have long development roads left (~3 years), but we believe the ~billion dollars market potentials presents a high reward for the risks. In addition, the COVID-19 opportunities may be significant (and quicker to market).

Current valuation attractive: We are maintaining our BUY rating, but lowering our 12-month price target to $7.50 from $8.00, which is based on a NPV analysis. We believe this valuation appropriately balances out the company's high risks with its high growth prospects and large upside opportunities.

Company Description

Based in Ocala, FL, AIM ImmunoTech is a biotech company engaged in the clinical development of new drug therapies for the treatment of viral, immune, and immuno-oncology based diseases.

Stock Data

Exchange:	NYSE
52-week Range:	$0.55 – 2.40
Shares Outstanding (million):	48
Market cap ($million):	$45
EV ($million):	$0
Debt ($million):	$0
Cash ($million):	$45
Avg. Daily Trading Vol. ($million):	$1
Float (million shares):	47
Short Interest (million shares):	1
Dividend, annual (yield):	$0 (NA%)

Revenues (US$ million)

	2022E (Cur.)	2022E (Old)	2023E (Cur.)	2023E (Old)
Q1 Mar	0.0A	0.1E	0.1E	
Q2 Jun	0.0E		0.0E	
Q3 Sep	0.0E		0.0E	
Q4 Dec	0.1E		0.1E	
Total	**0.2E**		**0.2E**	
EV/Revs	N/A		N/A	

Earnings per Share (pro forma)

	2022E (Cur.)	2022E (Old)	2023E (Cur.)	2023E (Old)
Q1 Mar	(0.08)A	(0.09)E	(0.09)E	
Q2 Jun	(0.08)E	(0.09)E	(0.09)E	
Q3 Sep	(0.08)E	(0.09)E	(0.09)E	
Q4 Dec	(0.08)E	(0.09)E	(0.09)E	
Total	**(0.33)E**	**(0.37)E**	**(0.35)E**	
P/E	N/A		N/A	

Important Disclosures

Ascendiant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 13.

Exhibit 1: AIM ImmunoTech's Overview

Source: Company reports

Exhibit 2: Company Development Pipeline





Source: Company reports.

Exhibit 3: Ampligen Market Opportunity



Source: Company reports.

Exhibit 4: Ongoing Ampligen Cancer Clinical Studies

Immuno-Therapy Targeting Multiple Cancers with High Unmet Need

- Locally Advanced Pancreatic Cancer – Phase 2 study IND cleared by the U.S. Food and Drug Administration ("FDA"). Study will compare the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Approximately 90 subjects expected to be enrolled across up to 30 centers in the U.S. and Europe. Study is on track to commence in Q3 2022.
- Advanced Recurrent Ovarian Cancer – Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer. Phase 1 portion was completed. The Phase 2 portion of the study is planned to be conducted in the future. ClinicalTrials.gov: NCT02432378
- Advanced Recurrent Ovarian Cancer – A follow-up Phase 2 study of advanced recurrent ovarian cancer using cisplatin and pembrolizumab, plus Ampligen; up to 45 patients to be enrolled; numerous patients have commenced treatment. ClinicalTrials.gov: NCT03734692
- Stage 4 Colorectal Cancer Metastatic to the Liver – Phase 2a study of Ampligen as a component of a chemokine modulatory regimen on colorectal cancer metastatic to liver was completed and met primary endpoint, evidenced by increased CD8a expression post-treatment (p=0.046); 19 patients were enrolled and 12 patients were evaluable. Data suggest that chemokine modulatory (CKM) regimen with Ampligen may be useful to enhance effectiveness of immunotherapies. Data from the Phase 2a study were presented in April 2022 at the American Association for Cancer Research (AACR) Annual Meeting 2022. ClinicalTrials.gov: NCT03403634
- Stage 4 Metastatic Triple Negative Breast Cancer – a Phase 1 study of metastatic triple-negative breast cancer using CKM therapy, including Ampligen and pembrolizumab, successfully met its primary endpoint. Eight patients were enrolled and 6 patients were evaluable. Positive data from this proof-of-concept study indicate that short-term systemic CKM followed by pembrolizumab is well-tolerated and selectively enhances local cytotoxic T-lymphocyte (CTL) infiltration in the tumor microenvironment (TME). The data from the Phase 1 study was presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 in April 2022. ClinicalTrials.gov: NCT03599453
- Early-Stage Prostate Cancer – Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy. Patient enrollment has been initiated in this study designed for up to 45 patients. ClinicalTrials.gov: NCT03899987
- Early-Stage Triple Negative Breast Cancer – Phase 1 study of chemokine modulation plus neoadjuvant chemotherapy in patients with early-stage triple negative breast cancer has received FDA authorization. The objective of this study is to evaluate the safety and tolerability of a combination of Ampligen and celecoxib with or without Intron A, when given along with chemotherapy. The goal of this approach is to increase survival. This study is recruiting patients and is designed for up to 24 patients. ClinicalTrials.gov: NCT04081389
- Refractory Melanoma – Phase 2 study that will evaluate polarized dendritic cell vaccine, interferon alpha-2, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma at Roswell Park. Up to 24 patients to be enrolled. ClinicalTrials.gov: NCT04093323
- Advanced Ovarian Cancer – AIM plans to develop a Phase 2 Cisplatin Resistant Advanced Recurrent Ovarian Cancer Clinical Study utilizing Ampligen at the University of Pittsburgh.

Source: Company reports.

Exhibit 5: Ampligen for COVID-19 and ME/CFS

Broad-Spectrum Immune System Response Against SARS-CoV-2 (COVID-19)

Previous animal studies yielded positive results utilizing Ampligen to treat Western Equine Encephalitis Virus, Ebola and SARS-CoV-1. The Company has also conducted laboratory experiments in SARS-CoV-2 showing Ampligen has a powerful impact on viral replication. The prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against SARS-CoV-2. AIM is currently evaluating the safety and effectiveness of intravenous Ampligen to reduce replication of SARS-CoV-2 virus from upper airway in patients in an ongoing Phase 1/2 study for the treatment of COVID-19 cancer patients. The Company also plans to conduct an intranasal study of Ampligen to potentially enhance and expand natural immunity.

Immune System Disorders (ISD): Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) / COVID-19 Long Hauler

The Company is currently sponsoring an expanded access program (EAP) for ME/CFS patients in the United States, and in 2021 AIM dosed its first "Long Hauler" patient with Ampligen in its post-COVID-19 "Long Hauler" portion of the active AMP-511 EAP in the United States. Patients receiving Ampligen in the ongoing AMP-511 EAP with Long Hauler/Post-COVID conditions (such as fatigue and cognitive function deficiency) have reported improvements after receiving Ampligen.



Source: Company reports.

Exhibit 6: AIM Upcoming Milestones (as of May 2022)

Source: Company reports.

Exhibit 7: Q1 2022 and Recent Highlights

– First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical potential with checkpoint inhibitors

– On track to commence Phase 2 study for lead program of Ampligen for pancreatic cancer Q3 2022

– Focus on further advancement of oncology pipeline and well-positioned to achieve multiple clinical and regulatory value-driving milestones throughout 2022

– Cash position of $44.5 million expected to fund company through the end of 2023

Recent Highlights

- Provided a summary of clinical data that support the potential of Ampligen® with checkpoint blockade therapies (see AIM's 4/21/22 press release).
- Engaged world-renowned CRO, Amarex Clinical Research LLC to conduct upcoming Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270).
- Presented data at the prestigious American Association for Cancer Research (AACR) Annual Meeting 2022:
  - *Negative impact of paclitaxel on human breast tumor microenvironment and its reversal by the combination of interferon-α with TLR3 agonist rintatolimod*
  - *Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver*
  - *Systemic Rintatolimod and Interferon-α2b selectively reprogram local tumor microenvironment in patients with metastatic triple negative breast cancer for enhanced influx of cytotoxic T-lymphocytes but not regulatory T-cells*
  - *Combined loco-regional and systemic, triple agent chemoimmunotherapy increases biomarkers of T cell chemotaxis in ovarian cancer*
- Received notification from the U.S. Food and Drug Administration ("FDA") that the FDA's Clinical Hold on AIM's investigational new drug ("IND") application for a Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270) has been lifted and the Company may proceed with the study.
- Announced the publication of positive data from a single-center, named-patient program treating advanced and metastatic pancreatic cancer patients (see: *Rintatolimod (Ampligen®) enhances numbers of peripheral B cells and is associated with longer survival in patients with locally advanced and metastasized pancreatic cancer pre-treated with FOLFIRINOX: a single-center named patient program*)
- Announced a contract for the strategic sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9 million.
- Appointed biotech and finance industry veteran Robert Dickey IV as Chief Financial Officer, effective April 4, 2022.
- Announced the publication of positive results from Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer.

Source: Company reports.

Exhibit 8: AIM ImmunoTech Stock Price (Five Years)

Source: https://bigcharts.marketwatch.com/

Exhibit 9: Consensus Expectations (as of May 16, 2022)

	Revenue (mil)	
	2022E	2023E
Q1 Mar	$0.7E	
Q2 Jun	$0.7E	
Q3 Sep		
Q4 Dec		
Total	$1.9E	$1.9E

	EPS	
	2022E	2023E
Q1 Mar	$(0.07)E	
Q2 Jun	$(0.07)E	
Q3 Sep		
Q4 Dec		
Total	$(0.32)E	$(0.34)E

**Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.*

Source: Company report, Refinitiv, and Ascendiant Capital Markets estimates

FINANCIAL MODEL

AIM ImmunoTech Inc.

Income Statement ($ mils)	Mar-20	Jun-20	Sep-20	Dec-20	2020	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	**0.0**	**0.0**	**0.0**	**0.0**	**0.2**	**0.0**	**0.0**	**0.0**	**0.1**	**0.1**	**0.0**	**0.0**	**0.0**	**0.1**	**0.2**	**0.0**	**0.0**	**0.0**	**0.1**	**0.2**
Cost of Revenues	0.2	0.2	0.2	0.2	0.8	0.2	0.3	0.2	0.2	0.9	0.1	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.1	0.3
Gross Profit	(0.2)	(0.2)	(0.2)	(0.2)	(0.6)	(0.2)	(0.3)	(0.1)	(0.1)	(0.7)	(0.0)	(0.0)	(0.0)	(0.1)	(0.2)	(0.0)	(0.0)	(0.0)	(0.1)	(0.2)
Research and development	0.9	1.5	1.1	2.3	5.7	1.4	1.3	2.0	2.9	7.7	1.0	2.0	2.0	2.0	7.0	2.0	2.0	2.0	2.0	8.0
General and administrative	2.3	1.7	2.1	2.6	8.7	2.1	2.1	1.8	2.6	8.7	2.1	2.0	2.0	2.0	8.1	2.2	2.2	2.2	2.2	8.8
Restructuring and other				0.1	0.1				1.8	1.8					0.0					0.0
Total operating expenses	3.2	3.2	3.2	5.0	14.5	3.5	3.5	3.8	7.3	18.1	3.1	4.0	4.0	4.0	15.1	4.2	4.2	4.2	4.2	16.8
Operating income (loss)	**(3.3)**	**(3.3)**	**(3.4)**	**(5.1)**	**(15.2)**	**(3.7)**	**(3.7)**	**(3.9)**	**(7.4)**	**(18.8)**	**(3.2)**	**(4.0)**	**(4.0)**	**(4.1)**	**(15.3)**	**(4.2)**	**(4.2)**	**(4.2)**	**(4.3)**	**(17.0)**
Interest income (expense)	(0.3)	(0.2)	0.0	0.0	(0.5)	0.0	0.0	(0.0)	(0.1)	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other income (expense)	(0.2)	0.2	0.0	1.2	1.2	0.1	(2.2)	0.1	1.7	(0.2)	(0.7)				(0.7)					0.0
Income before income taxes	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(3.8)	(4.0)	(4.0)	(4.1)	(16.0)	(4.2)	(4.2)	(4.2)	(4.3)	(17.0)
Income taxes					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(3.8)	(4.0)	(4.0)	(4.1)	(16.0)	(4.2)	(4.2)	(4.2)	(4.3)	(17.0)
Nonrecurring/noncash adjustments					0.0					0.0					0.0					0.0
Net income (pro forma)	**(3.8)**	**(3.4)**	**(3.3)**	**(3.9)**	**(14.4)**	**(3.6)**	**(5.9)**	**(3.8)**	**(5.8)**	**(19.1)**	**(3.8)**	**(4.0)**	**(4.0)**	**(4.1)**	**(16.0)**	**(4.2)**	**(4.2)**	**(4.2)**	**(4.3)**	**(17.0)**
EBITDA																				
Shares, Basic	17.5	30.0	38.9	41.0	31.8	45.7	47.8	47.8	47.8	47.3	48.0	48.1	48.2	48.3	48.1	48.4	48.5	48.6	48.7	48.5
Shares, Diluted	17.5	30.0	38.9	41.0	31.8	45.7	47.8	47.8	47.8	47.3	48.0	48.1	48.2	48.3	48.1	48.4	48.5	48.6	48.7	48.5
EPS Basic (Pro forma)	**($0.22)**	**($0.11)**	**($0.08)**	**($0.10)**	**($0.45)**	**($0.08)**	**($0.12)**	**($0.08)**	**($0.12)**	**($0.40)**	**($0.08)**	**($0.08)**	**($0.08)**	**($0.08)**	**($0.33)**	**($0.09)**	**($0.09)**	**($0.09)**	**($0.09)**	**($0.35)**
EPS Diluted (Pro forma)	($0.22)	($0.11)	($0.08)	($0.10)	($0.45)	($0.08)	($0.12)	($0.08)	($0.12)	($0.40)	($0.08)	($0.08)	($0.08)	($0.08)	($0.33)	($0.09)	($0.09)	($0.09)	($0.09)	($0.35)
Margins																				
Gross margin	-353%	-400%	-467%	-371%	-394%	-746%	-1113%	-376%	-247%	-530%	-133%	-100%	-100%	-100%	-106%	-100%	-100%	-100%	-100%	-100%
Research and development	1996%	3658%	3061%	5374%	3509%	5086%	5726%	6079%	5735%	5683%	3139%	4348%	5510%	3565%	4105%	6061%	4348%	5510%	3565%	4667%
General and administrative	5040%	4293%	5792%	6152%	5309%	7543%	9326%	5452%	5129%	6424%	6279%	4348%	5510%	3565%	4709%	6667%	4783%	6061%	3922%	5134%
Operating margin	-7389%	-8350%	-9319%	########	-9296%	-13375%	-16165%	-11906%	########	-13954%	-9552%	-8796%	########	-7230%	-8921%	########	-9230%	########	-7587%	-9902%
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	-8462%	-8425%	-9183%	-9324%	-8834%	-12782%	-25548%	-11594%	########	-14168%	-11576%	-8796%	########	-7230%	-9311%	########	-9230%	########	-7587%	-9902%
Y/Y % change																				
Total Revenue	#DIV/0!	38%	-41%	-16%	16%	-38%	-43%	-8%	21%	-17%	18%	100%	10%	10%	27%	0%	0%	0%	0%	0%
Gross margin	-31%	-14%	-1%	-7%	-15%	31%	60%	-26%	-19%	11%	-79%	-82%	-71%	-55%	-74%	-25%	0%	0%	0%	-6%
Research and development	-3%	33%	-7%	57%	23%	59%	-10%	82%	30%	34%	-27%	52%	0%	-32%	-8%	93%	0%	0%	0%	14%
General and administrative	28%	-12%	13%	74%	23%	-7%	25%	-14%	1%	0%	-2%	-7%	11%	-24%	-7%	6%	10%	10%	10%	9%
Operating income (loss)	14%	4%	5%	66%	22%	13%	11%	17%	45%	24%	-16%	9%	3%	-46%	-19%	34%	5%	5%	5%	11%
Net income (loss)	13%	66%	12%	230%	51%	-6%	74%	16%	49%	33%	7%	-31%	5%	-31%	-17%	11%	5%	5%	5%	6%
EPS Diluted (Pro forma)	-93%	-89%	-92%	-28%	-83%	-64%	9%	-6%	28%	-11%	2%	-32%	5%	-31%	-18%	10%	4%	4%	4%	5%

Source: Company reports and Ascendiant Capital Markets estimates.

AIM ImmunoTech Inc.

Balance Sheet ($ mils)	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Assets																
Cash and cash equivalents	27.6	33.9	38.5	38.5	48.8	41.1	37.3	32.1	29.0	32.4	28.0	24.1	21.0	17.6	13.0	8.8
Short term investments	0.5	1.1	1.1	0.5	1.2		0.5	16.2	15.6	15.6	15.6	15.6	15.6	15.6	15.6	15.6
Accounts receivable, net	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income taxes										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	1.6	0.1	0.1	1.3	1.2	0.2	0.2	1.9	5.8	0.2	0.2	0.3	0.2	0.2	0.2	0.3
Total current assets	29.7	35.2	39.8	40.3	51.2	41.3	38.0	50.2	50.4	48.2	43.7	40.0	36.7	33.4	28.8	24.6
Long term securities/investments	3.0	5.3	14.8	15.4	13.7	16.1	15.8			0.0	0.0	0.0	0.0	0.0	0.0	0.0
Property and equipment, net	7.0	6.8	6.6	6.5	6.3	6.1	6.0	4.0	0.1	0.1	(0.1)	(0.1)	(0.3)	(0.3)	(0.5)	(0.7)
Intangibles, net	1.2	1.4	1.4	1.5	1.8	1.8	1.8	2.0	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.5
Deferred income tax										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	1.5	1.5	1.5	0.9	1.1	1.3	1.4	1.5	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0
Total assets	**42.4**	**50.1**	**64.2**	**64.6**	**74.1**	**66.7**	**63.1**	**57.7**	**54.2**	**51.9**	**47.3**	**43.4**	**39.9**	**36.6**	**31.7**	**27.4**
Liabilities and stockholders' equity																
Accounts payable	0.2	0.3	0.2	0.4	0.2	0.5	0.4	0.2	0.4	0.9	0.7	0.6	0.7	0.9	0.7	0.6
Accrued expenses	0.3	0.3	0.3	0.4	0.5	0.4	0.4	0.4	0.3	1.4	0.7	0.6	1.0	1.4	0.7	0.6
Accrued interest										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred revenue										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.3	0.3	0.3	0.3	0.3
Short term debt	0.2	0.2	0.2	0.2	0.2					0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total current liabilities	**0.7**	**0.8**	**0.8**	**1.1**	**1.0**	**0.9**	**0.8**	**0.7**	**0.8**	**2.4**	**1.5**	**1.4**	**2.0**	**2.6**	**1.8**	**1.4**
Deferred income taxes										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Long term debt	6.2	2.0	1.9	1.9	1.8					0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total other liabilities	**6.6**	**2.3**	**2.3**	**2.2**	**2.2**	**0.3**	**0.3**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**
Preferred stock	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.8	1.0	1.3	1.5	1.7
Additional paid-in capital	366.2	381.4	398.9	402.5	416.0	416.4	416.8	417.2	417.5	417.5	417.5	417.5	417.5	417.5	417.5	417.5
Retained earnings	(331.9)	(335.3)	(338.6)	(342.0)	(345.6)	(351.4)	(355.3)	(361.1)	(364.9)	(369.0)	(373.0)	(377.1)	(381.3)	(385.5)	(389.8)	(394.0)
Treasury stock										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accumulated other comprehensive in	(0.0)	0.1	(0.0)	(0.0)	(0.2)	(0.2)	(0.3)			0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total stockholders' equity	**35.1**	**47.0**	**61.1**	**61.3**	**71.0**	**65.5**	**62.0**	**56.9**	**53.3**	**49.5**	**45.7**	**41.9**	**37.9**	**33.9**	**29.9**	**25.9**
Total stockholders' equity and liabil	**42.4**	**50.1**	**64.2**	**64.6**	**74.1**	**66.7**	**63.1**	**57.7**	**54.2**	**51.9**	**47.3**	**43.4**	**39.9**	**36.6**	**31.7**	**27.4**

Balance Sheet Drivers

	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Prepaid as % of total rev	3500%	295%	253%	3033%	4457%	674%	488%	3814%	17688%	500%	500%	500%	500%	500%	500%	500%
Accounts payable as % of total rev	367%	638%	569%	912%	675%	1961%	1118%	388%	1145%	2000%	2000%	1000%	2000%	2000%	2000%	1000%
Inventories as % of cost of rev	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Accrued expenses as % of total rev	636%	813%	894%	1052%	1779%	1622%	1097%	859%	994%	3000%	2000%	1000%	3000%	3000%	2000%	1000%
Activity Ratios																
A/R Days Sales Outstanding	92	104	65	73	109	110	76	0	0	70	70	70	70	70	70	70
Inventory Turnover	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
A/P Days Payable	73	115	90	174	72	145	212	101	442	900	900	450	900	900	900	450
Book & Cash Value (per share)																
Book Value per Share (diluted)	$2.01	$1.57	$1.57	$1.49	$1.55	$1.37	$1.30	$1.19	$1.11	$1.03	$0.95	$0.87	$0.78	$0.70	$0.62	$0.53
Cash per Share (diluted)	$1.78	$1.34	$1.40	$1.33	$1.39	$1.20	$1.12	$1.01	$0.93	$1.00	$0.90	$0.82	$0.76	$0.68	$0.59	$0.50
Net cash per Share (diluted)	$1.41	$1.27	$1.34	$1.27	$1.35	$1.20	$1.12	$1.01	$0.93	$1.00	$0.90	$0.82	$0.76	$0.68	$0.59	$0.50

Source: Company reports and Ascendiant Capital Markets estimates

AIM ImmunoTech Inc.

Cash Flow Statement ($ mils)	Mar-20	Jun-20	Sep-20	Dec-20	2020	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activities																				
Net income	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(3.8)	(4.0)	(4.0)	(4.1)	(16.0)	(4.2)	(4.2)	(4.2)	(4.3)	(17.0)
Depreciation	0.2	0.2	0.2	0.2	0.7	0.2	0.2	0.2	0.2	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortization	0.2	(0.1)	(0.0)	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0				0.0					0.0
Debt related amortization expen	0.2	(0.1)	0.0	0.0	0.1	0.0	0.0			0.0					0.0					0.0
Stock comp	0.2	0.1	0.3	0.4	1.0	0.5	0.5	0.3	0.2	1.6	0.2	0.2	0.2	0.2	1.0	0.2	0.2	0.2	0.2	1.0
Deferred income taxes					0.0	(0.2)	0.2	(0.5)	0.5	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Provision for bad debts				(0.0)	(0.0)					0.0					0.0					0.0
Reserves					0.0					0.0					0.0					0.0
Change in fair value of warrant l	0.2	(0.0)	(0.0)	(0.0)	0.1	0.0	(0.0)	(0.1)	(0.1)	(0.1)	(0.0)				(0.0)					0.0
Writedowns and impairments				1.4	1.4				1.8	1.8					0.0					0.0
Other gains/losses	(0.0)	0.2	(0.1)	(0.1)	0.0		2.0	0.6	(2.4)	0.2	0.7				0.7					0.0
Other		0.0	(0.1)	0.0	0.0	0.0	0.0	0.0	(0.0)	0.0	0.0				0.0					0.0
Changes in operating assets and liabilities:																				
Accounts receivable	(0.0)	0.8	0.0	(0.8)	0.0		0.0		0.0	0.0		(0.0)	0.0	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0
Inventory					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses & other curre	0.0	0.7	0.1	(0.1)	0.7	0.0	0.0	(0.0)	1.6	1.6	0.0	5.6	0.0	(0.1)	5.6	0.1	(0.1)	0.0	(0.1)	0.0
Income tax				(0.3)	(0.3)		1.1		(1.1)	0.0					0.0					0.0
Other assets	(0.0)	(0.0)	(0.2)	0.3	0.0	(0.0)	(0.0)	(0.0)	(0.5)	(0.6)	(0.0)	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0
Accounts payable	(0.3)	0.1	0.4	(0.3)	(0.1)	(0.2)	0.3	(0.1)	(0.2)	(0.2)	0.2	0.5	(0.2)	(0.2)	0.4	0.1	0.3	(0.2)	(0.2)	0.0
Accrued expenses	(0.1)	0.0	(0.2)	0.4	0.0	0.1	(0.1)	(0.0)	0.1	(0.0)	(0.1)	1.1	(0.7)	(0.2)	0.1	0.4	0.4	(0.7)	(0.2)	0.0
Accrued interest	0.1	0.1		0.0	0.2					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred revenue					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities					0.0					0.0		0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0
Net cash (used in) provided by	**(3.1)**	**(1.5)**	**(3.0)**	**(2.9)**	**(10.4)**	**(3.0)**	**(1.7)**	**(3.5)**	**(5.7)**	**(14.0)**	**(2.8)**	**3.4**	**(4.6)**	**(3.9)**	**(7.8)**	**(3.3)**	**(3.4)**	**(4.8)**	**(4.4)**	**(16.0)**
Cash flow from investing activities																				
Purchases of property and equi	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)		0.2	(0.0)	(0.0)	0.2		(0.0)	0.2	0.0	0.2	0.2	0.0	0.2	0.2	0.6
Purchases of short-term investn	3.8	(2.9)	(9.6)	0.1	(8.6)	0.9	(1.4)	(0.3)	0.5	(0.2)	(0.3)				(0.3)					0.0
Acquisitions	(0.3)			(0.3)	(0.6)	(0.4)		(0.1)	(0.1)	(0.6)	(0.0)				(0.0)					0.0
Other					0.0					0.0					0.0					0.0
Net cash used in investing acti	**3.5**	**(2.9)**	**(9.6)**	**(0.2)**	**(9.2)**	**0.5**	**(1.2)**	**(0.4)**	**0.4**	**(0.6)**	**(0.3)**	**(0.0)**	**0.2**	**0.0**	**(0.1)**	**0.2**	**0.0**	**0.2**	**0.2**	**0.6**
Cash flow from financing activities																				
Issuance of debt				(0.4)	(0.4)					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of debt	(0.1)	(4.4)	(0.1)	0.2	(4.3)	(0.1)	(4.8)	(0.0)	0.0	(4.9)					0.0					0.0
Issuance of stock	25.8	15.0	17.2	3.2	61.2	12.9		0.0	0.1	13.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repurchase of common stock					0.0					0.0					0.0					0.0
Proceeds from stock option exercises					0.0					0.0					0.0					0.0
Other					0.0					0.0					0.0					0.0
Dividends and distributions					0.0					0.0					0.0					0.0
Cash provided by (used in) fina	**25.7**	**10.7**	**17.2**	**3.0**	**56.6**	**12.8**	**(4.8)**	**0.0**	**0.1**	**8.2**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Effect of exchange rate on cash					0.0					0.0					0.0					0.0
Net increase (decrease) in cash	**26.1**	**6.3**	**4.6**	**0.0**	**37.0**	**10.3**	**(7.6)**	**(3.8)**	**(5.3)**	**(6.4)**	**(3.1)**	**3.4**	**(4.4)**	**(3.9)**	**(8.0)**	**(3.1)**	**(3.4)**	**(4.6)**	**(4.2)**	**(15.4)**
Beginning cash and equivalents	**1.5**	**27.6**	**33.9**	**38.5**	**1.5**	**38.5**	**48.8**	**41.1**	**37.3**	**38.5**	**32.1**	**29.0**	**32.4**	**28.0**	**32.1**	**24.1**	**21.0**	**17.6**	**13.0**	**24.1**
Ending cash and equivalents	**27.6**	**33.9**	**38.5**	**38.5**	**38.5**	**48.8**	**41.1**	**37.3**	**32.1**	**32.1**	**29.0**	**32.4**	**28.0**	**24.1**	**24.1**	**21.0**	**17.6**	**13.0**	**8.8**	**8.8**

Source: Company reports and Ascendiant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendiant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

AIM ImmunoTech Inc.



Source: https://bigcharts.marketwatch.com/

	Report Date		Price
Report	Date	Rating	Target
1	10/29/2018	Buy	33.00
2	11/21/2018	Buy	30.80
3	4/2/2019	Buy	28.60
4	5/16/2019	Buy	26.40
5	8/21/2019	Buy	6.00
6	11/17/2019	Buy	2.50
7	1/26/2020	Buy	3.00
8	4/4/2020	Buy	6.00
9	5/24/2020	Buy	7.00
10	8/21/2020	Buy	7.25
11	11/28/2020	Buy	7.50
12	4/6/2021	Buy	7.75
13	5/21/2021	Buy	8.00
14	9/7/2021	Buy	8.50
15	11/28/2021	Buy	8.75
16	4/12/2022	Buy	8.00

- Ascendiant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendiant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as

appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendiant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech stocks, and changes in consumer or government priorities for healthcare.

Ascendiant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendiant Capital Markets, LLC Rating System

Prior to January 31, 2014, ASCM used the following rating system:

Strong Buy: We expect the stock to provide a total return of 30% or more within a 12-month period.

Buy: We expect the stock to provide a total return of between 10% and 30% within a 12-month period.

Neutral: We expect the stock to provide a total return of between minus 10% and plus 10% within a 12-month period.

Sell: We expect the stock to provide a total return of minus 10% or worse within a 12-month period.

Speculative Buy: This rating is reserved for companies we believe have tremendous potential, but whose stocks are illiquid or whose equity market capitalizations are very small, often in the definition of a nano cap (below $50 million in market cap). In general, for stocks ranked in this category, we expect the stock to provide a total return of 50% or more within a 12-month period. However, because of the illiquid nature of the stock's trading and/or the nano cap nature of the investment, we caution that these investments may not be suitable for all parties.

Total return is defined as price appreciation plus dividend yield.

Ascendiant Capital Markets, LLC Distribution of Investment Ratings (as of April 17, 2022)

			Investment Banking Services Past 12 months	
Rating	**Count**	**Percent**	**Count**	**Percent**
Buy	41	98%	13	32%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	42	100%	13	31%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendiant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendiant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendiant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendiant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendiant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendiant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendiant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendiant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendiant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.